Trinity Biotech PLC NT 20-F, filed May 1, 2023
Trinity Biotech PLC (TRIB)
NT 20-F
2023-05-01
For: 2022-12-31
View Original
Added on
October 18, 2026
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
(Check one):
|
|
☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form
N-CSR
|
|
|
|
|
|
|
|
For Period Ended: December 31, 2022
|
|
|
|
☐ Transition Report on Form 10-K
|
|
|
|
☐ Transition Report on Form 20-F
|
|
|
|
☐ Transition Report on Form 11-K
|
|
|
|
☐ Transition Report on Form 10-Q
|
|
|
|
For the Transition Period Ended:
|
|
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A
PART I — REGISTRANT INFORMATION
TRINITY BIOTECH PLC
(Full Name of Registrant)
N/A
(Former Name if Applicable)
IDA Business Park, Southern Cross Road
(Address of Principal Executive
Office (Street and Number))
Bray, County Wicklow, A98 H5C8, Ireland
(City, State and Zip Code)
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate)
|
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
☒
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date;
and
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
On April 27, 2023, the Company closed the sale of its Fitzgerald Industries life sciences supply business. The divestiture of this
business required a significant amount of time and effort by the Company’s management. Accordingly, the Company’s management has been unable to devote the time and effort necessary to finalize and edgarize the Form 20-F for the fiscal year ended
December 31, 2022 by the filing deadline. The Company anticipates that the Form 20-F will be filed on or before May 15, 2023.
PART IV — OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
John Gillard
|
+353
|
12769800
|
|
(Name)
|
(Area Code)
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
The Company disseminated a press release dated March 23, 2023 describing its unaudited results of operations for the fourth quarter
and fiscal year ended December 31, 2022. The Company does not expect any material changes to its earnings press release furnished as Exhibit 99.1 to the Company's Current Report on Form 6-K filed March 27, 2023. In its earning press release the
Company reported revenues of $74.8m in 2022 and a net loss of $41.0m, compared to revenues of $93.0m and a net profit of $0.9m in 2021.
TRINITY BIOTECH PLC
(Name of Registrant as Specified in
Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date
|
May 1, 2023
|
By:
|
/s/ Aris Kekedjian
|
|
|
|
|
Aris Kekedjian
|
|
|
|
|
Chief Executive officer
|
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name
and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s
authority to sign on behalf of the registrant shall be filed with the form.
|
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
|